PTGX PROTAGONIST THERAPEUTICS, INC.
Research report · from SEC EDGAR · close 2026-07-13
$129.89 -1.2%
$8.35B mkt cap
executive summary
PROTAGONIST THERAPEUTICS, INC. (PTGX) is a $8.35B company. Revenue is $46.0M (-89.4% y/y) at a -283% net margin. It is not yet profitable. Our health score is A (88/100). 1 red flag on file. It funds itself; low dilution risk.
Revenue (FY)
$46.0M
-89.4% y/y
⚠One-sided insider selling
16 insider sales and no open-market buys in the recent window.
who's buying
Insider buys / sells
0 / 16
Cash & ST investments
$547.8M
Operating cash flow
$57.7M
Dilution shelf
active shelf
Assembled from SEC EDGAR (XBRL, Form 4, 13F, filings), STOCK Act disclosures, and end-of-day prices — every figure is real and sourced; nothing is fabricated or predicted. Filings lag 40–90 days. Educational, not investment advice. Generated 2026-07-13 by stocktools.ai.